Who should be tested for thrombophilia?

Genetics in Medicine

Volumn 13, Issue 1, 2011, Pages 19-20

  Moll, Stephan ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; GLYCINE; PROTHROMBIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FAMILY; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; NOTE; RECURRENT DISEASE; RISK FACTOR; SURGICAL TECHNIQUE; THROMBOPHILIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

GENETIC TESTING; HUMANS; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 78751627221     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3182088189     Document Type: Note

References (15)

1. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001;3:139-148.
2. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002; 126:1281-1295.
3. Nicolaides AN, Breddin HK, Carpenter P, et al. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol 2005;24:1-26.
4. Pernod G, Biron-Andreani C, Morange PE, et al. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc 2009;34:156-203.
5. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010;149:209-220.
6. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med 2011:13:67-76.
7. Schulman S, Lindmarker P, Holmström M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006;4:734-742.
8. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199-205.
9. Kearon C, Kahn SR, Agnelli G, Goldhaber SZ, Raskob GE, Comerota AJ. Antitthrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:454-545.
10. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009;301:2472-2485.
11. Lijfering WM, Middeldorp S, Veeger NJ, et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010;121:1706-1712.
12. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008;179:417-426.
13. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010;121:1630-1636.
14. Cosmi B, Palareti G. Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. Thromb Res 2010;125(suppl 2): S62-S65.
15. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: casefatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152:578-589.